7.5895

0.14% -0.0105

After Hours: 7.59 0.0005 +0.01%

Mink Therapeutics Inc (INKT)

Overview News Price History Financials Discussions Forecast

Mink Therapeutics Inc stock is traded at $7.5895, with a volume of 4,251. It is down -0.14% in the last 24 hours and down -9.76% over the past month. MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.

Previous Close:

$7.60

Open:

$7.56

24h Volume:

4,251

Relative Volume:

0.22

Market Cap:

$29.75M

Revenue:

Net Income/Loss:

$-24.77M

P/E Ratio:

-10.40

EPS:

-0.73

Net Cash Flow:

$-17.36M

1W Performance:

+1.19%

1M Performance:

-9.76%

6M Performance:

+5.41%

1Y Performance:

-22.56%

1-Day Range:

$7.24

$7.9487

1-Week Range:

$7.20

$7.97

52-Week Range:

$4.5601

$13.79

Mink Therapeutics Inc Stock (INKT) Company Profile

Name

Mink Therapeutics Inc

Sector

Healthcare (1150)

Industry

Biotechnology (676)

Phone

212-994-8250

Address

149 FIFTH AVENUE, NEW YORK

Employee

Twitter

Next Earnings Date

2024-08-13

Latest SEC Filings

INKT's Discussions on Twitter

Compare INKT with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
INKT Mink Therapeutics Inc	7.5895	29.75M	0	-24.77M	-17.36M	-0.73
VRTX Vertex Pharmaceuticals Inc	500.19	127.64B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	603.58	65.95B	14.09B	4.50B	2.96B	39.28
ARGX Argen X Se Adr	656.65	37.92B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	273.55	32.98B	2.35B	-269.70M	-75.39M	-2.09
ONC Beigene Ltd Adr	254.16	26.92B	3.81B	-644.79M	-669.77M	-6.24

Mink Therapeutics Inc Stock (INKT) Latest News

12:41 PM

MiNK Therapeutics to Announce Q1 2025 Financial Results and Host Conference Call on May 15th - Nasdaq

12:41 PM

12:31 PM

MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report - GlobeNewswire

12:31 PM

12:30 PM

Clinical-Stage Biotech MiNK Therapeutics Sets Q1 Earnings Date: Key iNKT Cell Therapy Updates Expected - Stock Titan

12:30 PM

04:07 AM

Geode Capital Management LLC Lowers Stock Position in MiNK Therapeutics, Inc. (NASDAQ:INKT) - Defense World

04:07 AM

Apr 23, 2025

Learn to Evaluate (INKT) using the Charts - news.stocktradersdaily.com

Apr 23, 2025

Apr 19, 2025

Comparing Atyr PHARMA (NASDAQ:ATYR) and MiNK Therapeutics (NASDAQ:INKT) - Defense World

Apr 19, 2025

Apr 13, 2025

LIfT BioSciences appoints new CSO - Bdaily

Apr 13, 2025

Apr 07, 2025

LIfT BioSciences Appoints Mark A. Exley as Chief Scientific Officer - EIN News

Apr 07, 2025

ImmunityBio to Host Key Opinion Leader and Investor Meeting to Provide Updates on Clinical Programs and ANKTIVA Commercial Launch - Business Wire

Apr 07, 2025

Apr 06, 2025

(INKT) Trading Report - news.stocktradersdaily.com

Apr 06, 2025

Mar 30, 2025

Reviewing MiNK Therapeutics (NASDAQ:INKT) & Creative Medical Technology (NASDAQ:CELZ) - The AM Reporter

Mar 30, 2025

Mar 27, 2025

MiNK Therapeutics, Inc. (NASDAQ:INKT) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 19, 2025

MiNK Therapeutics (NASDAQ:INKT) Given Buy Rating at HC Wainwright - Defense World

Mar 19, 2025